Positive interim results observed in ongoing study of HBV vaccine

VBI Vaccines Inc. announced positive interim clinical results from an ongoing phase 1b/2a study of VBI-2601 (BRII-179), a novel recombinant, protein-based immunotherapeutic candidate for the treatment of chronic hepatitis B infection.According to a press release, VBI Vaccines collaborated with Brii Biosciences.“These early data from the low-dose cohorts are very encouraging and provide a human proof-of-concept that leads us to believe VBI-2601 (BRII-179) could be an effective and critical component of a functional cure for chronic hepatitis B patients,” Jeff Baxter, VBI’sRead More

Share on facebook
Share on twitter
Share on linkedin